Arca
Skip to content

Palmoplantar pustulosis

Drug research and approvals for palmoplantar pustulosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 8 studies of palmoplantar pustulosis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 9 drug trials for it since 2013.

  • Recruiting worldwide: 8
  • Trials authorized in Canada: 9
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 8 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

Newest first; search them all in Canada trials
Sep 23, 2026A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of sonelokimab in participants with palmoplantar…SONELOKIMABMOONLAKE IMMUNOTHERAPEUTICS AGOngoing
Oct 21, 2025A phase 3, randomized, double-blind, placebo-controlled, multicenter study with open-label extension to evaluate the efficacy and safety of bimekizumab in…BIMEKIZUMABUCBOngoing
May 8, 2025A proof-of-concept phase 2a, double-blind, 2-arm trial to investigate efficacy and safety of twice daily delgocitinib cream 20 mg/g compared with cream vehicle…DELGOCITINIBLEO PharmaOngoing
Nov 17, 2021A randomized, double-blind, placebo-controlled, dose ranging phase 2 study to evaluate the efficacy and safety of rist4721 in subjects with palmoplantar…RIST4721ARISTEA THERAPEUTICS INCOngoing
May 28, 2020An open-label, single arm, long term trial of spesolimab treatment in patients with palmoplantar pustulosis (ppp) who have completed previous bi spesolimab…SPESOLIMAB (BI 655130)BOEHRINGER INGELHEIM (CANADA) LTD LTEEClosed
Jun 19, 2019Multi-center, double-blind, randomised, placebo-controlled, phase IIb dose-finding study to evaluate efficacy and safety of different subcutaneous doses of bi…BI 655130BOEHRINGER INGELHEIM (CANADA) LTD LTEEOngoing
Mar 20, 2019A phase II, randomized, placebo-controlled, double-blind, multiple dose study to evaluate the efficacy and safety of anb019 in subjects with palmoplantar…ANB019ANAPTYSBIO INCClosed
Nov 30, 2018A randomized, double-blind, placebo-controlled, phase 2a study to evaluate the efficacy and safety of rist4721 in subjects with palmoplantar pustulosisRIST4721ARISTEA THERAPEUTICS INCClosed
Mar 28, 2017Multi-center, double-blind, randomised, placebo-controlled, phase IIa study to investigate efficacy, safety,tolerability, pharmacokinetics and pharmacogenomics…BI 655130BOEHRINGER INGELHEIM (CANADA) LTD LTEEClosed

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.